GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (FRA:BJX1) » Definitions » Capital Expenditure

BioLife Solutions (FRA:BJX1) Capital Expenditure : €-3.10 Mil (TTM As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is BioLife Solutions Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

BioLife Solutions's cash flow for capital expenditures for the three months ended in Mar. 2025 was €-0.16 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2025 was €-3.10 Mil.

BioLife Solutions Capital Expenditure Historical Data

The historical data trend for BioLife Solutions's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLife Solutions Capital Expenditure Chart

BioLife Solutions Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.81 -7.42 -9.80 -5.85 -3.37

BioLife Solutions Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.33 -0.92 -1.00 -1.01 -0.16

BioLife Solutions Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €-3.10 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioLife Solutions Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BioLife Solutions Inc (FRA:BJX1) » Definitions » Capital Expenditure
Comparable Companies
PLSE KMTS STAA AZTA EMBC ATRC ANGO NNNN SMTI LMAT ISRG XPAR:EL BDX TSE:7741 XSWX:ALC RMD TSE:4543 OCSE:COLO B XPAR:DIM XSWX:STMN
Traded in Other Exchanges
BLFS:USA BJX1:Germany
Address
3303 Monte Villa Parkway, Suite 310, Bothell, WA, USA, 98021
Website
https://www.biolifesolutions.com
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.

BioLife Solutions Headlines

No Headlines